Home » Blog » Election Impact, Moonshot, and Big Pharma

Election Impact, Moonshot, and Big Pharma


IP Blog | Dave Melin | November 13, 2016

BioBlog WeeklyThis week’s BioBlog focuses on the impact the election results will have on cancer research and the Cancer Moonshot, UHG’s national ACO, and Big Pharma drug pricing.

Biopharma Stocks Jump as Americans Vote for Trump

In this article Fierce Biotech reports the surprising impact that the election results had on biopharma stocks.

The Fate of Cancer Moonshot in 2017

According to AJMC.com Vice President Joe Biden’s Cancer Moonshot initiative will be in limbo due to the results of this past week’s election.

What the Trump Presidency Means for Cancer Care, the ACA, and the Moonshot

In this piece from the Cancer Letter, there is speculation that Trump’s unanticipated victory upended what many in oncology expected to be a smooth transition for federal priorities in health care. Clinton had pledged to “take up the charge” on the moonshot, whereas the Trump campaign was mum on the subject (The Cancer Letter, Sept. 23).

UnitedHealth Group Launches National ACO

Forbes Magazine reports that UnitedHealth Group, the nation’s largest health insurer, will launch a nationally branded accountable care organization, committing more resources to a value-based care push designed to attract self-funded employers.

Under Drug-Cost Attack, Big Pharma CEOs Raise the Value-Based Pricing Flag

In recent days, Novartis chief Joe Jimenez and Amgen CEO Robert Bradway, among others, have spoken out publicly about pegging drug costs to their results as reported in this article by FiercePharma.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *